Assessment of renal concentrating ability.

Delin, Krister; Aurell, M; Bendz, Hans

doi:10.1136/bmj.1.6167.888-d

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravenous administration, on the other hand, does not result in maximum urinary osmolatity [10]. Although in tranasal DDAVP has been used routinely in renal con centration tests there are no data as to the actual uptake of the substance through the nasal mucosa.…”

Section: Discussionmentioning

confidence: 96%

Subcutaneous and Intranasal Administration of 1-Deamino-8-<i>d</i>-Arginine Vasopressin in the Assessment of Renal Concentration Capacity

Tryding¹,

Sterner²,

Berg³

et al. 1987

Nephron

View full text Add to dashboard Cite

Maximum urine concentration capacity was studied in healthy adults using different routes and doses of administration of 1-deamino-8-d-arginine vasopressin (DDAVP) – desmopressin. Plasma levels of DDAVP showed a dose-dependent increase after the subcutaneous but not after the intranasal administration. The effect on urine osmolality was similar but more prolonged after the subcutaneous as compared to the intranasal route. We conclude that subcutaneous injection is a simple and reliable way of administering DDAVP. A dose of 4 μg in adults is optimum diagnostically and it corresponds to 20–40 μg administered intranasally.

show abstract

Section: Discussionmentioning

confidence: 96%

Subcutaneous and Intranasal Administration of 1-Deamino-8-<i>d</i>-Arginine Vasopressin in the Assessment of Renal Concentration Capacity

Tryding¹,

Sterner²,

Berg³

et al. 1987

Nephron

View full text Add to dashboard Cite

show abstract

“…We observed even a nonsignificantly higher maximal urine osmolality obtained after intranasal administration which may be partly due to the exact quantity of dDAVP administered by spray applicator. This would be in favor of the observation of Delin et al [4] that intravenous administration of dDAVP did not induce a maximal urinary concentration. One can also speculate about the optimal intravenous dose whether it should be more than 10% of the intranasal dose in order to obtain a 'real' maximal urine osmolality.…”

Section: Commentsmentioning

confidence: 57%

“…Monson et al [3] and Delin et al [4] reported on intramuscular dDAVP administration in adults and found it to be equivalent to the intranasal route. In addition, both subcutaneous and intramuscular administration can be painful and.…”

Section: Commentsmentioning

confidence: 99%

Renal Concentrating Capacity Test by Desmopressin in Children: Intranasal or Intravenous Route?

Feber

Cochat²,

Hadj‐Aïssa³

et al. 1993

Am J Nephrol

View full text Add to dashboard Cite

Intranasal administration of desmopressin (dDAVP) is frequently used to test renal concentrating capacity in children. However, the bioavailability of intranasal dDAVP is about 10% and may be modified by nasal congestion. The study aimed to compare the efficacy of intranasal dDAVP with an equivalent dose of intravenous dDAVP for a renal concentrating capacity test in children. We studied 18 children aged 12.6 ± 3.8 years weighing more than 20 kg in whom a dDAVP test was indicated as part of global renal function evaluation. Spray applicator (Minirin Spray) was used for intranasal administration (20-40 ug according to BW); the dose of intravenous dDAVP (Minirin IV) was reduced to 10% (2-4 ug according to BW). A randomized sequence was used for the first intranasal or intravenous dDAVP test; the second alternate test was repeated in the same children in a time interval ranging from 1 to 3 weeks. Osmolality of the urine (Uosm, mosm/kg) was determined before (TO), then 2 (T2) and 4 (T4) h after dDAVP administration. There was no significant difference in Uosm at TO (intranasal = 480 ± 212, intravenous = 443 ± 168 mosm/kg), T2 (604 ± 226 and 542 ± 173 mosm/kg, respectively), and T4 (657 ± 206 and 629 ± 190 mosm/kg, respectively). There was an obvious correlation between intranasal and intravenous Uosm at T4 (r² = 0.826; p = 0.001). Even if intravenous dDAVP is of theoretical interest, intranasal administration of dDAVP using a spray applicator can be considered as first-choice method for a renal concentrating capacity test in children weighing more than 20 kg.

show abstract

Reference values for renal concentrating capacity in children by the desmopressin test

et al. 1992

View full text Add to dashboard Cite

Reference values are reported for maximal renal concentrating capacity in children using intranasally administered desmopressin. The report is based on 591 tests in 473 healthy children aged 0.5-13 years. The concentrating capacity increased markedly during the first years of life and reached a plateau at the age of 3 years. The mean value minus two standard deviations was 525 mosmol/kg at 1 year of age and 825 mosmol/kg at 3 years of age.

show abstract

Assessment of renal concentrating ability.

Abstract: both, is still lacking, there is enough evidence to require further investigation of the subject.

Cited by 4 publications

References 1 publication

Subcutaneous and Intranasal Administration of 1-Deamino-8-<i>d</i>-Arginine Vasopressin in the Assessment of Renal Concentration Capacity

Subcutaneous and Intranasal Administration of 1-Deamino-8-<i>d</i>-Arginine Vasopressin in the Assessment of Renal Concentration Capacity

Renal Concentrating Capacity Test by Desmopressin in Children: Intranasal or Intravenous Route?

Reference values for renal concentrating capacity in children by the desmopressin test

Contact Info

Product

Resources

About